Cynthia A. Challener

Bioconjugation requires aseptic manufacturing and containment for cytotoxic payloads.

Advances in single-use technologies, sensors, and cell retention systems facilitate processes designed for the long run.

Bioconjugation requires aseptic manufacturing and containment for cytotoxic payloads.

The maturation of single-use technologies presents commercial bioprocessing options for small-volume drug products.

Automation can improve many aspects of bioprocessing, but several hurdles must be overcome before the full range of benefits can be realized.

Biopharma seeks alternatives that meet the needs for next-gen biologic drug production.

More complex biologic samples must be evaluated to ever higher levels of specificity and sensitivity.

More advanced NGS-based techniques still require validation and regulatory acceptance.

More published data and initial regulatory approvals are needed to drive adoption of continuous bio-manufacturing.

Access to multiple analytical techniques is essential for fully characterizing complex protein formulations.

Early adopters are benefiting from lower costs and increased productivity.

Greater clarity on the application of existing regulations will accelerate development of cell and gene therapies.

Gene therapies highlight FDA new drug approvals in 2017.

Advances in TFF and single-use systems help advance UF/DF on the continuous processing path.

Single-use systems provide replaceable fluid paths.

The use of approved platform technologies can reduce the time and cost required to generate new vaccines.

Anna Kireieva/Shutterstock.comSpeed to market is essential in the biopharmaceutical industry today.

Single-use and single-pass TFF devices are facilitating advances in biopharma manufacturing.

Choosing a suitable material for fill/finish containers begins during the product development stage.

Improved resin chemistries and customized separation solutions are enabling more efficient separations.

Media manufacturers are focused on reducing risk, improving quality and consistency, and managing costs.

Increased understanding of potential impurities has spurred efforts to standardize monitoring procedures.

The unique structures of fusion proteins lead to expression, heterogeneity, and stability issues.

Including next-gen antibodies in pharma pipelines is considered essential for future success.

The decision to use disposable bioreactors is now driven by commercial rather than technological considerations.

Despite limitations, mass spec is having an impact on biologic drug development and manufacturing.

Excipient selection strongly influences lyophilization performance for biologic drugs.

There is much work to do to achieve efficient, cost-effective production processes.

Advances in technology are increasing the productivity and efficiency of commercial-scale chromatography bioprocesses.

Multiparticulates are increasingly used due to their flexibility in providing controlled-release, fixed-dose combinations, ease of taste-masking, and suitability for pediatric applications